NEW YORK (TheStreet) -- CHANGE IN RATINGS

Atheros Communications

( ATHR) upgraded at FBR from Market Perform to Outperform. $43 price target. Recent checks suggest that business is robust.

Endo Pharmaceuticals

(ENDP) - Get Report

downgraded at Goldman from Buy to Neutral. $27 price target. Stock lacks near-term catalysts.

F5 Networks

(FFIV) - Get Report

downgraded at Canaccord to Hold. Valuation call, based on an $80 price target.

First Horizon

(FHN) - Get Report

downgraded at KBW to Market Perform. $14 price target. Estimates also cut.

Juniper Networks

(JNPR) - Get Report

upgraded at Canaccord to Buy. $35 price target. Company is positioned well to grow into 2011.

King Pharmaceuticals

( KG) upgraded at Goldman to Neutral from Sell. Valuation call, based on a $9.50 price target.

Perrigo

(PRGO) - Get Report

downgraded at Goldman to Sell. $50 price target. Valuation call, as the stock is up 44% year-to-date.

Safe Bulkers

(SB) - Get Report

downgraded at BofA/Merrill to Buy from Neutral. The Baltic Dry Index (BDI) hints at a slowdown in China's growth. Price target trimmed to $8 from $9.50.

Temple-Inland

( TIN) downgraded at Goldman from Buy to Neutral. Valuation call, as the sector is seeing lower pulp prices.

Teekay Taankers

(TNK) - Get Report

upgraded at BofA/Merrill to Buy from Neutral. Investment benefits dividend. Price target jumped to $15 from $12.50.

WellCare Health Plans

(WCG) - Get Report

reinstated at BofA/Merrill with a Buy rating and $29 price target. WCG is launching a turnaround strategy as an arduous FBI investigation of accounting errors closes.

Yahoo!

(YHOO)

upgraded at ThinkEquity from Hold to Buy. Company should see continued improvement in display growth and stabilizing search market share.

STOCK COMMENTS / EPS CHANGES

Alliance Data

(ADS) - Get Report

target boosted at Goldman. Shares of ADS now seen reaching $63. Credit quality improved in June. Neutral rating.

Amylin Pharmaceuticals

( AMLN) price target cut at Citi to $25 from $27 on higher Bydureon costs. 2010 and 2011 EPS estimates increased to -$0.70 and -$0.32, respectively. Maintain Buy rating.

Bank of America

(BAC) - Get Report

cut from Conviction Buy List at Goldman. Company is showing relatively little credit improvement.

Bank of America

(BAC) - Get Report

numbers reduced at FBR. Shares of BAC now seen reaching $18. Estimates also cut, given mounting margin pressures.

Bank of America

(BAC) - Get Report

price target cut at Barclays from $21 to $19. Interchange hit and reduced revenues cloud outlook. Maintain Equal Weight rating.

Walt Disney

(DIS) - Get Report

target cut at Morgan Stanley. Shares of DIS now seen reaching $40. Parks segment should be hurt by lower consumer confidence. Overweight rating.

General Electric

(GE) - Get Report

price target lower at Credit Suisse by a dollar to $22. Higher aviation R&D costs and ongoing subdued energy demand outlook. Maintain Outperform rating. EPS estimates for 2010/2011/2012 set at $1.11/$1.37/$1.68, respectively.

General Electric

(GE) - Get Report

price target lower at Barclays to $20 from $25. Headwinds in 2011 offset GE cap strength. 2010 EPS estimate increased to $1.15, 2011 lowered to $1.35. Maintain Overweight rating.

Genuine Parts

(GPC) - Get Report

numbers raised at Goldman. Shares of GPC now seen reaching $48. Estimates also increased, given stronger acceleration in the industrial business.

Jarden

(JAH)

price target trimmed at Citi to $44 from $48 on rising costs. Cheap stock with strong long-term prospects. Maintain Buy rating.

Johnson & Johnson

(JNJ) - Get Report

estimates increased at UBS through 2011. Company seeing higher sales. Buy rating and $75 price target.

Kimberly-Clark

(KMB) - Get Report

numbers increased at Goldman through 2012. Company will be helped by lower pulp prices. Sell rating and new $58 price target.

Microsoft

(MSFT) - Get Report

price target cut at Citi to $31 from $37. Client inputs remain positive, secular concerns front and center. Maintain Buy rating.

Microsoft

(MSFT) - Get Report

estimates raised at UBS through 2011. Company seeing higher growth in Windows. Buy rating and $38 price target.

PMC-Sierra

(PMCS)

estimates upped at Goldman through 2012. ADPT acquisition should add to earnings. Neutral rating.

Solarfun

( SOLF) target, estimates raised at Barclays. SOLF price target increased to $8 from $10. Recent euro strength and robust 2H10 fundamentals could drive near-term positive momentum, Barclays said. 2010 and 2011 EPS estimates jumped to $1.45 and $1.15, respectively.

Verizon

(VZ) - Get Report

price target trimmed at Barclays. VZ price target lowered to $31 from $32. Expect continued wireline margin weakness. Maintain Equal Weight rating.

Verizon

(VZ) - Get Report

target, estimates cut at Deutsche. Shares of VZ now seen reaching $36. On the other hand, estimates were cut because of the access line spin-off to FTR. Buy rating.

This article was written by a staff member of TheStreet.